Home › Research › Health systems and care delivery
Healthcare costs among patients with dementia‐related psychosis: Comparing dementia with Lewy bodies with other dementias
Victor Abler, Nazia Rashid, Ben Skoog, Rachel Halpern, Scott H. Bunner, Monica Frazer. Alzheimer s & Dementia, 2020-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Abstract Background DLB is the second‐most common form of degenerative dementia and it’s unclear whether healthcare costs differ for patients with DLB and Alzheimer’s disease. [1],[2]. The differential presentation of psychosis among dementias[3] may affect healthcare costs. [1] Bostrom F, Jonsson L, Minthon L, Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer’s disease. Int J Geriatr Psychiatry 2007;22(8):713‐719. [2] Zhu CW, Scarmeas N, Stavitsky D, Albert M, Brandt J, Blacker D, Sano M, Stern Y. Comparison of costs of care between patients with Alzheimer’s disease and dementia with Lewy Bodies, Alzheimer’s Dementia, July 2008; 4(4):280‐284. [3] Tzeng R, Tsai C, Wang C, Wang T, Chiu P. Delusions in patients with dementia with Lewy bodies and the associated factors. Behavioural Neurology, 2018:1‐8. Method This claims data analysis examined commercial and Medicare Advantage with Part D (MAPD) enrollees aged ≥40 years with evidence of psychosis (antipsychotic (AP) treatment lasting ≥45 days or ≥1 AP pharmacy fill+≥1 psychosis diagnosis) and ≥2 diagnoses for the same type of dementia from 01Jun2016–31May2018. The earliest AP fill was the index date. Continuous insurance enrollment was required for 12 months before and after index. DRP and DLB patients were matched 1:1. Patient characteristics and healthcare costs were analyzed descriptively. Result Matched DLB and DRP cohorts (n=442 each) had average age of 78.3 years, were 53.6% male, and 89.8% had MAPD coverage. 44% of DRP patients had ≥2 Alzheimer’s diagnoses and 32% had ≥2 unspecified dementia diagnoses. DLB patients had a significant pre‐index to post‐index increase for total all‐cause healthcare costs (from $5,392 to $8,046, p<0.01) while pre/post differences among DRP patients were not significant. DLB patients had significantly higher mean post‐index pharmacy costs for all‐cause ($6,616 vs. $4,515), dementia‐related ($810 vs. $675) and psychosis‐related ($2,344 vs. $623) medications, and higher mean psychosis‐related total healthcare costs ($5,801 vs. $2,687) than DRP. Conclusion DLB patients had higher medication and psychosis‐related costs than DRP patients who had other dementias.
What this study adds
Evidence grade: Low
The record lists 442 participants. This study compared healthcare costs between patients with dementia with Lewy bodies and other dementias who had psychosis, finding that DLB patients had a significant increase in total all-cause healthcare costs. Reported effect size: 53.6%; 89.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Abler, V., Rashid, N., Skoog, B., Halpern, R., Bunner, S. H., & Frazer, M. (2020). Healthcare costs among patients with dementia‐related psychosis: Comparing dementia with Lewy bodies with other dementias. Alzheimer s & Dementia. https://doi.org/10.1002/alz.047091
Vancouver
Abler V, Rashid N, Skoog B, Halpern R, Bunner SH, Frazer M. Healthcare costs among patients with dementia‐related psychosis: Comparing dementia with Lewy bodies with other dementias. Alzheimer s & Dementia. 2020. doi:10.1002/alz.047091.
BibTeX
@article{abler2020-1a65cff1,
author = {Abler, Victor and Rashid, Nazia and Skoog, Ben and Halpern, Rachel and Bunner, Scott H. and Frazer, Monica},
title = {{Healthcare costs among patients with dementia‐related psychosis: Comparing dementia with Lewy bodies with other dementias}},
journal = {Alzheimer s \& Dementia},
year = {2020},
doi = {10.1002/alz.047091},
url = {https://doi.org/10.1002/alz.047091}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Result Matched DLB and DRP cohorts (n=442 each) had average age of 78.3 years, were 53.6% male, and 89.8% had MAPD coverage. 44% of DRP patients had ≥2 Alzheimer’s diagnoses and 32% had ≥2 unspecified dementia diagnoses.
- DLB patients had a significant pre‐index to post‐index increase for total all‐cause healthcare costs (from $5,392 to $8,046, p<0.01) while pre/post differences among DRP patients were not significant.
- DLB patients had significantly higher mean post‐index pharmacy costs for all‐cause ($6,616 vs. $4,515), dementia‐related ($810 vs. $675) and psychosis‐related ($2,344 vs. $623) medications, and higher mean psychosis‐related total healthcare costs ($5,801 vs. $2,687) than DRP.
Why it matters
This study compared healthcare costs between patients with dementia with Lewy bodies and other dementias who had psychosis, finding that DLB patients had a significant increase in total all-cause healthcare costs. It addresses costs of care, not treating, curing, or preventing Alzheimer's disease.
Study details
- Participants442
- Effect size53.6%; 89.8%
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 442 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Monica Frazer: h-index 11 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Optum (United States): institution h-index 114 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.